(2-氨基-5-甲氧基苯基)-(3-氟苯基)甲酮 | 849435-46-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (2-氨基-5-甲氧基苯基)-(3-氟苯基)甲酮
• 英文名称: (2-amino-5-methoxyphenyl)(3-fluorophenyl)methanone
• 英文别名: (2-amino-5-methoxyphenyl)-(3-fluorophenyl)methanone
• CAS: 849435-46-7
• 化学式: C₁₄H₁₂FNO₂
• 分子量: 245.253
• InChiKey: RPDBFOPOJZDCLS-UHFFFAOYSA-N

物化性质

• 沸点：
  431.4±45.0 °C(Predicted)
• 密度：
  1.238±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2-氨基-5-甲氧基苯基)-(3-氟苯基)甲酮 在 potassium hydroxide 、 肼 作用下， 以 四氢呋喃 、 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.54h， 生成 4-(5-(4-chlorophenyl)-3-(4-(3-fluorophenyl)-6-methoxy-2-oxo-1,2-dihydroquinolin-3-yl)-4,5-dihydro-1H-pyrazol-1-yl)-4-oxobutanoic acid
  参考文献：
  名称：

  Structure–Activity Relationships and Pharmacophore Model of a Noncompetitive Pyrazoline Containing Class of GluN2C/GluN2D Selective Antagonists

  摘要：

  Here we describe the synthesis and structure-activity relationship for a class of pyrazoline-containing dihydroquinolone negative allosteric modulators of the NMDA receptor that show strong subunit selectivity for GluN2C- and GluN2D-containing receptors over GluN2A- and GluN2B-containing receptors. Several members of this class inhibit NMDA receptor responses in the nanomolar range and are more than 50-fold selective over GluN1/GluN2A and GluN1/GluN2B NMDA receptors, as well as AMPA, kainate, GABA, glycine, nicotinic, serotonin, and purinergic receptors. Analysis of the purified enantiomers of one of the more potent and selective compounds shows that the S-enantiomer is both more potent and more selective than the R-enantiomer. The S-enantiomer had an IC50 of 0.17-0.22 mu M at GluN2D- and GluN2C-containing receptors, respectively, and showed over 70-fold selectivity over other NMDA receptor subunits. The subunit selectivity of this class of compounds should be useful in defining the role of GluN2C- and GluN2D-containing receptors in specific brain circuits in both physiological and pathophysiological conditions.

  DOI：

  10.1021/jm400652r
• 作为产物：
  描述：

  5-甲氧基靛红酸酐 在 正丁基锂 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 、 正己烷 为溶剂， 反应 2.17h， 生成 (2-氨基-5-甲氧基苯基)-(3-氟苯基)甲酮
  参考文献：
  名称：

  Structure–Activity Relationships and Pharmacophore Model of a Noncompetitive Pyrazoline Containing Class of GluN2C/GluN2D Selective Antagonists

  摘要：

  Here we describe the synthesis and structure-activity relationship for a class of pyrazoline-containing dihydroquinolone negative allosteric modulators of the NMDA receptor that show strong subunit selectivity for GluN2C- and GluN2D-containing receptors over GluN2A- and GluN2B-containing receptors. Several members of this class inhibit NMDA receptor responses in the nanomolar range and are more than 50-fold selective over GluN1/GluN2A and GluN1/GluN2B NMDA receptors, as well as AMPA, kainate, GABA, glycine, nicotinic, serotonin, and purinergic receptors. Analysis of the purified enantiomers of one of the more potent and selective compounds shows that the S-enantiomer is both more potent and more selective than the R-enantiomer. The S-enantiomer had an IC50 of 0.17-0.22 mu M at GluN2D- and GluN2C-containing receptors, respectively, and showed over 70-fold selectivity over other NMDA receptor subunits. The subunit selectivity of this class of compounds should be useful in defining the role of GluN2C- and GluN2D-containing receptors in specific brain circuits in both physiological and pathophysiological conditions.

  DOI：

  10.1021/jm400652r

文献信息

• [EN] BENZODIAZEPINE BROMODOMAIN INHIBITOR<br/>[FR] INHIBITEUR DE BROMODOMAINES VIS-À-VIS DE LA BENZODIAZÉPINE
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2011054845A1

  公开（公告）日：2011-05-12

  Benzodiazepine compounds of formula (I), and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy, in particular in the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.

  苯二氮卓类化合物的化学式（I）及其盐，含有这类化合物的药物组合物以及它们在治疗中的应用，特别是在治疗溴结构域抑制剂适应症的疾病或症状。
• Quinoline potassium channel inhibitors
  申请人：Dinsmore J. Christopher

  公开号：US20070078154A1

  公开（公告）日：2007-04-05

  The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.

  本发明涉及具有结构式（I）的化合物，其作为钾通道抑制剂用于治疗心律失常等。
• Benzodiazepine Bromodomain Inhibitor
  申请人：Bailey James

  公开号：US20120252781A1

  公开（公告）日：2012-10-04

  Benzodiazepine compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.

  公式（I）的苯二氮平化合物及其盐，含有这种化合物的制药组合物以及它们在治疗中的使用。
• [EN] QUINOLINE POTASSIUM CHANNEL INHIBITORS<br/>[FR] INHIBITEURS DES CANAUX POTASSIQUES A LA QUINOLEINE
  申请人：MERCK & CO INC

  公开号：WO2005030129A3

  公开（公告）日：2005-05-26
• QUINOLINE POTASSIUM CHANNEL INHIBITORS
  申请人：Merck & Co., Inc.

  公开号：EP1667973A2

  公开（公告）日：2006-06-14